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ABSTRACT
Prospective clinical trials for blood transplantation and BMT are made more difficult by limited patient
numbers, heterogeneity of clinical management strategies, and high-intensity therapy with frequent and toxic
competing hazards. To address the challenges of prospective clinical study of BMT, the Blood and Marrow
Transplant Clinical Trials Network (BMTCTN), sponsored by the National Heart, Lung, and Blood Institute/
National Cancer Institute, was established. The network’s charge is to design and execute multicenter clinical
trials requiring participation from the network and from noncore centers for successful performance and to
address rare diseases and unique populations that could not be well studied in individual centers. The BMT
CTN organizational structure, current portfolio of studies, and scientific agenda are reviewed. Opportunities
for investigators in any institution to propose trials and participate are outlined.
© 2007 American Society for Blood and Marrow Transplantation
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fNTRODUCTION
The complex ﬁeld of hematopoietic stem cell
ransplantation (HSCT) involves the transfer of BM,
lood, or umbilical cord derived hematopoietic pro-
enitor and stem cells for the treatment of numerous
ife-threatening blood, immune, and metabolic disor-
ers and support for treatment of numerous cancers.
ince 1968 when the ﬁrst successful allogeneic
SCTs were reported, thousands of transplantations
ave been performed. Although annually 45 000
orldwide and 20 000 US HSCTs are performed,
heir use in management of leukemias, lymphomas,
ultiple myeloma, immune deﬁciency disorders, mar-
ow failure states, metabolic diseases, hemoglobinop-
thies, and autoimmune disorders has broadened their
pplicability but greatly expanded the heterogeneity of
he procedures. Donor types may be related or unre-
ated or the patient’s own autologous cells. Cell
ources may be marrow, ﬁlgrastim- mobilized periph-
ral blood, or umbilical cord blood (UCB). The in-
ensity of treatment may vary; it can be applied to
oung and old and can be performed with curative ex-
ectations for some indications and as clinically valuable,
ut palliative, treatment for others. Although 100 US Henters perform transplantations, each year the average
umber per center is 40 and in most centers (other
han the largest few) only a few transplantations are
erformed for the same disease, with the same approach,
nd the same donor type during each year.
Accordingly, this heterogeneity has fostered the
evelopment of highly variable treatment approaches
temming from scientiﬁc creativity and from institu-
ional practice and habit. This heterogeneity has also
mpeded determination of best practices or ap-
roaches with broad applicability. The motivation of
ransplantation centers to pool their experience to
enerate sufﬁciently large datasets for meaningful
linical analyses has also hampered the determination
f best practices. Collaborative sharing of recipient
utcomes has been facilitated by studies performed
hrough the Center for International Blood and
arrow Transplant Research (CIBMTR), an afﬁli-
tion of the research department of the National
arrow Donor Program (NMDP) and the previous
nternational Bone Marrow Transplant Registry,
nd the Autologous Blood and Marrow Transplant
egistry (IBMTR/ABMTR) and other groups per-
orming retrospective observational study regarding
SCT outcomes.
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D. Weisdorf et al.258Prospective studies have been limited by the pau-
ity of cases at each center, restricted funding, and by
ifferent institutional management approaches to in-
ividual diseases. In the past, prospective trials have
een facilitated by collaborations among individual
nvestigators, by cooperative multi-institutional can-
er groups, by disease-speciﬁc consortia, or by phar-
aceutical industry support, although industry studies
re most often directed at testing single speciﬁc drugs.
Recognizing these limitations in prospective
SCT trials, in 2001, the National Heart, Lung, and
lood Institute (NHLBI) and the National Cancer
nstitute (NCI) jointly established a Blood and Mar-
ow Transplant Clinical Trials Network (BMT CTN)
o study novel HSCT methods and management strat-
gies in a more efﬁcient multicenter setting. The net-
ork’s scientiﬁc goals are to study means to improve
he safety and efﬁcacy of the transplantation proce-
ure and improve successful therapy of speciﬁc dis-
ases. These goals focusing on HSCT serve to com-
lement those of cancer cooperative groups or
isease-speciﬁc consortia that focus on determining
he best treatment options for a given condition.
he network includes 16 core centers or consortia
Appendix) and 50 noncore centers that actively
articipate in network studies. Logistical and statis-
ical support is provided by a data and coordinating
enter (DCC) formed through the collaboration of
MDP, CIBMTR, and the EMMES Corporation
see BMTCTN.net or CIBMTR.org or Emmes.
om). Noncore centers enroll subjects in trials
hrough the DCC and, importantly, individuals
rom any center may propose trials for consider-
tion. We review the network goals, progress to
ate, and opportunities for new multicenter studies.
MT CTN SCIENTIFIC MISSION
The network’s principal charge is to develop and
erform studies of clinical and scientiﬁc importance,
o design and execute studies that require the multi-
enter collaborations of a large network, and to per-
orm studies that can improve the health and safety of
ransplant recipients throughout the United States
nd internationally. The scientiﬁc agenda was set
orth in 6 topic areas originally deﬁned by the State of
he Science Conferences sponsored by the NHLBI,
CI, CIBMTR, and American Society for Blood and
arrow Transplantation (ASBMT). These areas in-
lude (a) alternative donors and graft sources; (b) reg-
men-related toxicity; (c) GVHD, (d) disease recur-
ence; (e) infection and immune reconstitution, and (f)
ate effects and quality of life (QOL). Within this
cientiﬁc framework, the BMT CTN has focused its
cientiﬁc agenda and developed trials to help improve
ey clinical outcomes. The BMT CTN also recog- (ized the unique ability of the network’s collaborative
ower to develop trials in rare diseases and popula-
ions where special approaches are necessary to en-
ance accrual. The opportunity to integrate data
rom completed BMT CTN studies in the design of
ubsequent trials, to support hypothesis-generating
ncillary laboratory-based studies, and to educate
nvestigators about the unique value and conduct of
ulticenter trials are additional intangible beneﬁts.
MT CTN PARTICIPATION
The network portfolio of studies is developed by a
teering committee, including representatives of the
6 core centers, funding agencies, and invited experts.
umerous investigators from core and 50 noncore
enters also actively participate, with target enroll-
ent of 4000 patients in active trials and 1400 en-
olled in the ﬁrst 30 mo of open accrual. Individual
nvestigation teams organize and present phase II data
o aid development of network trials. Speciﬁc network
ommittees also propose protocols that focus on key
uestions requiring network resources for successful
ompletion.
CTIVE AND FUTURE STUDIES
BMT CTN trials directed toward the key scien-
iﬁc questions comprise the study portfolio for the
etwork.
raft Sources
BMT CTN #0201: BM versus ﬁlgrastim (G-CSF)
obilized PBSCs for unrelated donor HSCT.
Since the early 1990s several small phase II studies
ollowed by numerous randomized trials of allografts
sing ﬁlgrastim-mobilized PBSC versus marrow from
atched sibling donors demonstrated more rapid en-
raftment, but a trend to more frequent acute and
hronic GVHD because some studies showed supe-
ior survival with PBSC. PBSC has replaced BM
80% of related donor allografts and for nearly 75%
f unrelated donor (URD) transplants. No evidence,
owever, supports this radical shift to use of PBSCs for
RD transplantation and a large retrospective compar-
tive analysis demonstrates no net advantage for the use
f PBSC in this setting. As a consequence, BMT CTN
0201 identiﬁed this key question to be tested in a
rospective randomized trial comparing BM with G-
SF-mobilized PBSC as a source of stem cells for
RD transplantation. The trial will test the hypoth-
sis that PBSCs accelerate engraftment and result in
ore complete immunologic recovery and improved
verall 2-yr survival and QOL. Eligible patients in-
lude those with leukemia, myelodysplastic syndrome
MDS), or lymphoma with a closely matched (5 or 6 of
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BMT Clinical Trials Network 259HLA-antigen) matched URD. Five hundred ﬁfty
atients are planned for enrollment to detect a 12.5%
ifference in overall 2-yr survival. Important second-
ry endpoints will include formal assessment of im-
une reconstitution and QOL in donors and recipi-
nts. Continuing trial modiﬁcations have reduced
arriers to enrollment, including the addition of the
argest European donor center, the addition of Cana-
ian transplantation centers, and broadening of eligi-
ility criteria to include additional conditioning and
VHD prophylaxis regimens. This prospective trial is
niquely capable of answering a critical question that
ill have a powerful effect on the use of URD trans-
lants for years to come.
Only 50%–75% of patients have an available well-
atched URD depending on racial, ethnic, and HLA
olymorphisms. Therefore, alternative graft sources
equire investigation. UCB from URDs may be a
iable alternative using only partially matched donor
rafts, and thus markedly increasing the availability of
uitable donor grafts for racial and ethnic minority
atients. Supporting this contention are data that only
2% of BM or PBSC transplants during 2005 were for
thnic minorities compared with 27% of UCB trans-
lants during the same period. A major limitation of
ord blood is the ﬁxed, small number of cells available
or infusion. This has restricted applicability of UCB
ransplants to children. One potential advance in en-
ancing successful engraftment, the use of 2 closely
atched UCB units, has achieved encouraging sur-
ival results in early studies. The network plans a
ormal prospective trial (BMT CTN #0501) compar-
ng transplantation using single versus dual cord blood
nits in treatment of pediatric patients to determine
hether the administration of 2 UCB units is feasible
nd may improve the success of engraftment, might
educe relapse, and is not associated with new toxici-
ies or unique morbidities. To test the trial hypothesis
hat using 2 UCB units will improve 1-yr survival by
2%, 190 patients will be enrolled.
Another extension of graft source options is a
ulticenter phase II study to evaluate UCB as a source
f stem cells for nonmyeloablative transplantation.
ased on data from the University of Minnesota, a
onmyeloablative regimen using cyclophosphamide,
udarabine, and low-dose TBI plus cyclosporine and
ycophenolate mofetil (MMF) could induce high
ates of engraftment, limited peritransplant morbidity,
nd encouraging survival for patients unsuitable for
reatment with fully myeloablative regimens. A
lanned study anticipates enrollment of 50 patients to
stimate the primary endpoint (6-mo survival) of
75%.
A strategy testing the use of haploidentical trans-
lantation, where a ﬁrst-degree relative donor is
early always available, will also be explored within
he BMT CTN. Early studies from Johns Hopkins tnd the Fred Hutchinson Cancer Research Center
eport encouraging data using a nonablative condi-
ioning regimen employing cyclophosphamide, ﬂu-
arabine, TBI, and a second dose of cyclophospha-
ide given 3 d after transplantation to eliminate
lloreactive T cells in conjunction with post-trans-
lantation cyclosporine plus MMF.
egimen-Related Toxicity
Regimen-related toxicities still plague patients in
heir early transplantation course with mucositis,
eno-occlusive disease, pneumonitis, alveolar hemor-
hage, enteritis, and complicating infection from dis-
uption of mucocutaneous infectious barriers. Net-
ork efforts to address this area in 2 trials have been
ormalized and further plans to assess a study format
o carefully test the utility and applicability of reduced
ntensity allografting in adults are being developed.
The ﬁrst study (BMT CTN #0502) is a multi-
enter collaboration with the NCI-sponsored cooper-
tive oncology group CALGB to test reduced inten-
ity allogeneic transplantation from a best available
elated donor or URD in patients with AML in CR1
0–75 yr of age, a group with poor outcomes after
onventional chemotherapy alone. This study, using
educed intensity ﬂudarabine plus busulfan, will pro-
ide feasibility data for future comparison with the
est available nontransplantation approaches for man-
gement of AML in this older population who are
raditionally excluded from prospective transplanta-
ion studies.
A second network study (BMT CTN #0403) will
rospectively test etanercept against placebo to treat
he high mortality complication of idiopathic pneu-
onia syndrome (IPS) after allogeneic transplanta-
ion. IPS occurs in up to 20% of HSC transplant
ecipients and contributes to50% of post-transplan-
ation nonrelapse deaths. IPS comprises a diffuse al-
eolar injury without infection and stems from direct
pithelial toxicity exaggerated by inﬂammatory cyto-
ines and other factors. Based on pilot data from the
niversity of Michigan, the network will evaluate the
tility of etanercept in initial therapy of IPS to im-
rove 28-d survival without need for supplemental
xygen. This trial will also evaluate inﬂammatory cy-
okine secretion in alveolar ﬂuid and secondary infec-
ious complications. The high acuity of this syndrome
nd the complexity in its management makes it un-
ikely that, outside the deﬁned infrastructure of the
MT CTN, any other group could attempt a study of
his type requiring 120 patients.
A third trial (BMT CTN #0301) is testing a dose
eduction in cyclophosphamide to limit the peritrans-
lantation toxicity of conditioning for patients with
evere aplastic anemia receiving unrelated donor HSC
ransplant. In this rare disease, the multicenter net-
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D. Weisdorf et al.260ork will enroll up to 64 patients to test the safety of
stepwise reduction in conditioning intensity without
n increase in graft rejection. This trial opened in
006 and will complete accrual within 2 yr.
raft-versus-Host Disease
GVHD is the single most important complication
f allogeneic HSCT. Its toxicity and required immu-
osuppressive therapy result in prolonged hospitaliza-
ion, multiorgan dysfunction, secondary opportunistic
nfections, and treatment lethality. Although aspects
f its pathophysiology are well studied in rodent pre-
linical models, primary treatment of aGVHD still
elies on corticosteroids and calcineurin inhibitors and
as not changed over the past 25 yr. Based on pilot
ata from several centers, the BMT CTN has initiated
MT CTN #0302, a randomized, prospective phase
I trial testing 4 new agents (etanercept, pentostatin,
MF, and denileukin diftitox [ONTAK]) along with
orticosteroids for initial treatment of aGVHD, all of
hich show some improvement in response rates in
atients with GVHD. The use of these agents in
ombination with corticosteroids may augment com-
lete response rates at day 28 (the primary trial end-
oint) allowing more rapid steroid tapering, helping
o eliminate the morbidity of prolonged steroid ther-
py, and thereby reduce secondary infections and im-
rove overall GVHD control. One hundred eighty
atients are planned for enrollment through 2007.
ncillary studies including cutaneous immunopathol-
gy, cytokine polymorphisms, and secretion will be
ncluded to enhance understanding of the effect of
hese different immunosuppressive and anti-inﬂam-
atory agents in the management of aGVHD.
The network has also developed novel GVHD
rophylaxis trials. Based on data from the Dana-Far-
er Cancer Institute, a new combination of sirolimus
lus tacrolimus offers the possibility of improved
VHD control without the morbidity of methotrex-
te, which delays engraftment and exaggerates mu-
ositis and other toxicities. Prospective comparison of
irolimus plus tacrolimus versus methotrexate plus ta-
rolimus (BMT CTN #0402) will be initiated in late
006 to formally and prospectively evaluate the utility
f this promising new agent in preventing GVHD.
A second approach, prophylaxis of aGVHD
hrough ex vivo T cell depletion of donor cells, has
een studied for decades without deﬁnitive conclu-
ions. Based on data from Memorial Sloan-Kettering
ancer Center, a multicenter phase II trial (BMT
TN #0303) will test whether these promising single-
enter results can be replicated using CD34 selected
llografts for patients with good risk (CR1 and CR2)
ML undergoing sibling donor transplantation. This
-center phase II trial uses the Miltenyi CliniMacs
evice for CD34 selection and will target 6-mo dis- uase-free survival 75%, which would justify future
roader phase III comparisons.
Chronic GVHD is perhaps the single most vexing
nd protracted morbid complication that accompanies
llogeneic transplantation. Limited understanding of
ts pathophysiology and restricted approaches to its
anagement have been compounded by its long-term
ature, the insidious onset of symptomatology often at
emote distances from the transplantation center, and
plethora of clinical manifestations. A recent NCI-
ponsored comprehensive approach outlined elements
o understand the pathophysiology and management
f cGVHD. This consensus project (published serially
n Biology of Blood and Marrow Transplantation from
ctober 2005 to May 2006) outlines formal ap-
roaches to diagnosis and staging, biomarkers, clinical
rials, supportive care, and other features of the syn-
rome. No recommendations for improvements in
herapy have yet been made. The BMT CTN is de-
eloping a randomized multiarm approach testing
romising new agents to control steroid-resistant
GVHD using sirolimus, rituximab, or high-dose
ethylprednisolone, each added to prednisone plus
alcineurin inhibitors to provide high-frequency and
urable responses to cGVHD. The goal will be to
imit the morbidity, infectious burden, and mortality
ccompanying this syndrome. Multiparameter mea-
urements of response will test the consensus criteria
nd determine the generalizability of these measure-
ents in evaluating patients with cGVHD.
isease Recurrence
Although these trials seek to broaden the applica-
ion of and limit the toxicity of HSCT, for some
iseases and particularly for autologous HSCT, dis-
ase recurrence is the most frequent cause of treat-
ent failure. This requires imaginative new efforts to
dentify patients best able to beneﬁt from new thera-
eutic approaches.
In multiple myeloma, although autografting has
een well accepted as a useful treatment for over a
ecade, disease relapse is expected, even after tandem
utografting. Two new approaches are being studied
o improve progression-free survival. In BMT CTN
0102, the network is testing tandem autologous stem
ell transplants versus autografting followed by a re-
uced intensity sibling donor allograft to control ac-
ive disease and prevent early disease recurrence with-
ut excessive morbidity from GVHD. In the tandem
uto arm, a second randomization will test thalido-
ide plus dexamethasone maintenance therapy to
urther determine whether extended progression-
ree survival with limited morbidity can be achieved.
his trial targeting 600 patients will complete
ccrual by 2007 and planning for a follow-up trial is
nderway.
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BMT Clinical Trials Network 261In diffuse large B cell lymphoma, autografting is
ell accepted as the best curative approach for pa-
ients after initial relapse. However, treatment failure
s disease recurrence still plagues nearly 50% of au-
ograft recipients. A newly opened prospective trial
ests the use of radioiodine anti-CD20 (Bexxar) to
upplement BCNU (carmustine), etoposide, cytara-
ine, melphalan (BEAM) chemotherapy condition-
ng to reduce relapse and improve disease-free sur-
ival without additional morbidity or late toxicities
ncluding MDS and secondary leukemia. Based on
romising data from the University of Nebraska,
MT CTN #0401 will prospectively test BEAM
ersus Bexxar-BEAM for pretransplantation condi-
ioning for patients with large cell lymphoma, tar-
eting 224 patients to detect a 20% improvement in
-yr progression-free survival.
Future post-transplantation studies may consider
doptive cell therapies, post-transplantation mainte-
ance, or techniques to augment a graft-versus-malig-
ancy reaction to improve disease control and expand
he success of transplant treatments.
nfection and Immune Reconstitution
The profound immunosuppression needed to
acilitate allografting and prevent rejection also ren-
ers patients highly vulnerable to a broad array of
pportunistic infections. The most common life-
hreatening opportunistic infections after allotrans-
lantation are invasive fungi. In BMT CTN #0101
e have tested voriconazole versus ﬂuconazole in a
linded, randomized trial to evaluate its utility in
reventing mycotic infection after allotransplanta-
ion. The primary endpoint is fungal-free survival at
ay 180 with secondary endpoints evaluating the
tility of the galactomannan assay in predicting
nd/or conﬁrming the presence of mycotic infec-
ion, toxicity, and need for secondary antifungal
herapy. With the new availability of multiple po-
ent antifungal agents, their formal and prospective
omparisons in well-designed and blinded trials are
he only tools available to determine their value in
reventing these most lethal infectious complica-
ions.
Functional immune recovery to prevent such in-
ections is also being addressed as a formal endpoint in
he prospective trial comparing marrow with G-CSF-
obilized PBSC after URD grafting (BMT CTN
0201). Future studies under consideration include
valuating the relevance and timing of post-transplan-
ation immunizations, a formal assessment of T cell
ecovery to decide on duration of post-transplantation
nfectious/antimicrobial prophylaxis, and mechanisms
o enhance pathogen-speciﬁc immunity. pate Effects and QOL
Although survival free of relapse is the primary
oal of HSCT, functional and full recovery without
ontinuing morbidity, health impairment, social or
hysiological burdens, and other late effects is of
reater importance as larger numbers of transplanta-
ion patients seek return to full health and happy
ong-term recovery. A lengthy list of late effects after
SCT may include iron overload, pulmonary com-
romise, hyperthyroidism, cataracts, bone loss, im-
aired memory or psychosocial adjustment, fatigue,
rowth retardation, and infertility in addition to sec-
ndary malignancy. Measurement of the multidimen-
ional QOL and determining predictors and most
mportantly preventive and coping strategies to reduce
ts morbidity are critical for management of patients
njoying longer survival after successful HSCT. Im-
roved capacity to comprehend, measure, and identify
eans to improve patients’ recovery and QOL represent
n important added parameter of success for any new
herapy. Accordingly, late effects will be addressed
hrough BMT CTN studies through extended fol-
ow-up and by assessment of patient- reported QOL
utcomes in 2 speciﬁc trials (#0201 BM versus peripheral
lood in URD HSCT and #0102 tandem HSCT for
yeloma). Ongoing evaluation of these more complex,
ut important outcome parameters in future trials will
nhance the added value of patient participation and
mprove understanding of patients’ needs for full recov-
ry.
articipation in New BMT CTN Proposals
The collective creativity of the HSCT community is
eeded to design the most important trials for future
tudy. Investigators at core centers, participating non-
ore centers, and at any institutions are invited to submit
deas, outlines, or formal proposals for trials to be con-
idered within the BMT CTN (see BMTCTN.net).
lthough resources, logistical feasibility, and most often
stimates of patient accrual are important milestones in
etting and implementing new trials, the best ideas are
till the limiting step in any scientiﬁc venture. Creative
pproaches will attract attention, scientiﬁc interest, and
ew funding to enhance the mission and success of
etwork participation. All investigators are welcome and
ll ideas will be given fair hearing. Great ideas that
urpass the available resources of the BMT CTN can
till be encouraged. The BMT CTN will partner with
thers to identify supplemental resources and is commit-
ed to assist investigators in developing new studies, new
dvances, and new improvements in HSCT. We are
urrently planning a “State of the Science” symposium
o be held in Ann Arbor, Michigan in June 2007 that will
ring together experts from outside the network and
teering committee members to identify the most com-
elling opportunity for clinical trials in the next 3-4 yr.
At
a
p
s
C
e
d
i
t
n
a
t
A
t
N
A
B
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
B
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
D. Weisdorf et al.262reas for Ongoing Study
Rare diseases, particularly in children or minori-
ies, cannot be well studied in single sites or even an
ggregate of interested centers. The recruitment for
rospective testing in rare diseases requires wide-
pread collaboration for an effective study. The BMT
TN has encouraged pediatric investigators inter-
sted in metabolic diseases and hemoglobinopathies to
evelop plans for new HSCT trials. Additional studies
n other uncommon conditions may also be proposed
o capitalize on the infrastructural resources of the
etwork and aid investigators in development of new
pproaches, particularly for underserved or impor-
antly, understudied populations.
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MT CTN Core Centers
Case Western Reserve University (Consortium)
City of Hope
Dana Farber Cancer Institute
Duke University
Fred Hutchinson Cancer Research Center
Johns Hopkins University
Memorial Sloan-Kettering Cancer Center
Pediatric Blood and Marrow Transplant Consor-
tia
Stanford University Medical Center (Stanford
Hospital and Clinics)
University of California at San Diego/SCRIPPS
(Consortium)
University of Florida
University of Michigan
University of Minnesota
University of Nebraska
University of Pennsylvania
University of Texas, MD Anderson Cancer Cen-
ter
MT CTN Non-core Centers
Arizona Cancer Center/University of Arizona
Avera Hematology & Transplant Center
Baylor College of Medicine/The Methodist Hos-
pital
Baylor University Medical Center
BC Cancer Agency, Vancouver
BMT Group of Georgia/Northside Hospital
Cancer Centers of the Carolinas
CancerCare Manitoba BMT ProgramCentre Hospitalier L’hotel Dieu de Québec
CHA Hopital Enfant-Jesus, Quebec
Children’s Healthcare of Atlanta
Children’s Hospital Los Angeles
Christiana Care Health System
DeKalb Medical Center
Emory University
Fox Chase/Temple University/BMT Program
H. Lee Mofﬁtt Cancer Center
Hackensack Univ. Medical Center
Hamilton Health Sciences, McMaster Site
Hospital Maisonneuve-Rosemont, Montreal
Indiana BMT at Beech Grove
Indiana University Medical Center/Riley Hospi-
tal
Jewish Hospital BMT Program
Kansas City Cancer Centers
Karmanos Cancer Institute/BMT
Loyola University Medical Center
Mayo Clinic
Medical College of Wisconsin
Monteﬁore Medical Center
Mount Sinai Medical Center
Ohio State/Arthur G. James Cancer Hospital
Ottawa Hospital, General Campus
Providence Portland Medical Center
Queen Elizabeth II Health Sciences Centre,
Halifax
Rocky Mountain BMT Program
Roswell Park Cancer Institute
Saskatoon Cancer Center
Texas Transplant Institute
Tom Baker Cancer Centre, Calgary
Tufts-New England Medical Center
Tulane University Hospital
University of Alabama at Birmingham
University of California, San Francisco
University of Iowa Hospitals and Clinics
University of Maryland Medical Systems/Green-
baum Cancer Center
University of Miami
University of Oklahoma Medical Center
University of Pittsburgh Cancer Institute
University of Rochester Medical Center
University of Toronto/Princess Margaret Hospi-
tal
University of Wisconsin Hospital & Clinics
Utah BMT/University of Utah Med School
Vancouver General Hospital
Vanderbilt University
Virginia Commonwealth University MCV Hos-
pitals
Wake Forest University Health Sciences
Yale University School of Medicine/Yale-New
Haven Hospital
